This research looked at patient-reported outcomes and survival data from the randomized ALICE trial. The study involved 68 patients with metastatic triple-negative breast cancer who received either chemotherapy plus atezolizumab or chemotherapy plus a placebo. Follow-up lasted for 12 months.
The results showed that adding atezolizumab led to statistically significant improvements in global quality of life, emotional functioning, and pain compared to placebo. Progression-free survival was also improved in patients who had higher quality of life scores at the start of the treatment.
However, patients with lower quality of life scores at baseline did not see an improvement in progression-free survival when treated with atezolizumab. The study noted sustained tolerability over the 12-month period, with no specific adverse events reported in the provided data. Readers should understand that because the sample size was small, these findings are preliminary and may not apply to all patients.